Blue Water and ARCH Venture led a $85m Series C funding round in Vizgen.

Blue Water, a California-based hedge fund manager, and ARCH Venture, a venture capital firm, led a $85m Series C funding round in Vizgen, a biotech company that develops solutions for next-generation spatially resolved, single-cell transcriptomics, with participation from Sofina, Northpond Ventures, Tao Capital Partners and Novalis LifeSciences. "Single-cell spatial genomics is a true game-changer in how we are able to understand complex biological systems and it is incredibly gratifying to see how the research community is embracing our ground-breaking MERSCOPE platform for unparalleled genomics insights, accelerating biological research and discovery. Today’s financing news is a testament to the power and potential of Vizgen’s industry leading spatial genomics technology and we are still only at the cusp of what we can provide our customers in our quest to improve human health," Terry Lo, Vizgen President and CEO.